Resonance Health Limited (ASX: RHT) is pleased to announce the expansion of TrialsWest with a new clinical trial site opening in Mandurah, WA in August 2025. This addition significantly increases participant capacity and allows for enhanced recruitment for major pharma trials managed by Resonance Health Group. The strategic location of the Mandurah Site in a rapidly growing city presents a substantial opportunity for future growth.

CEO Mr. Andrew Harrison expressed confidence in the expansion’s potential, highlighting the company's focus on growth from diverse pharma customers and trials. The strategic approach of targeting affordable, densely populated areas with good transport links aligns with future expansion plans. Additional new sites will be pursued along with complementary acquisitions in the coming periods.

Investors are invited to view Mr. Harrison's video discussion on the expansion on the Company’s InvestorHub and can find further information on the TrialsWest network on our website. Questions and inquiries are welcome, and stakeholders are encouraged to engage with Resonance Health through our social media channels.

Resonance Health remains committed to delivering high-quality healthcare technology and services globally, with a range of regulatory cleared products for managing human diseases and supporting clinical trials. The Company's dedication to scientific rigor and quality has enabled it to achieve regulatory clearances and certifications for its innovative products and services. Join us in our mission by registering your interest on our website and following us on social media platforms.